ArticleJournal of the Pediatric Infectious Diseases Society2026
Incidence of Invasive Pneumococcal Disease in US Children by Risk Group, 1998-2023.
Article in Journal of the Pediatric Infectious Diseases Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundChildren with risk conditions are vulnerable to invasive pneumococcal disease (IPD) and are targeted for routine and supplemental pneumococcal vaccination. This study aimed to quantify the incidence of IPD in US children by risk group since pneumococcal conjugate vaccine introduction.
methodsInvasive pneumococcal disease episodes were identified in the Merative™ MarketScan® Commercial Database (1998-2023) and Multi-State Medicaid Database (2001-2023) using inpatient and outpatient claims. Annual IPD incidence rates (IRs) were calculated as episodes per 100 000 person-years (PY) for children <18 years of age, overall and by insurance type, age, and risk group. Incidence rate ratios (IRRs) were calculated to compare IR for children with chronic medical conditions (CMC) and immunocompromising conditions (IC) with those with no CMC/IC.
resultsA total of 3538 commercially-insured and 3268 Medicaid-insured children with ≥1 IPD episode were identified among 128.9 million (121.9 million PYs) and 71.2 million eligible children (65.4 million PYs), respectively. Across age and risk groups, IPD IRs decreased over time, regardless of insurance type. Commercially-insured children with CMC and IC had 3.1-8.6 and 19.1-74.5 times higher IPD IRs, respectively, than those without CMC/IC, with similar patterns in the Medicaid database. Invasive pneumococcal disease IRs were the highest among children <2 years, while risk-group disparities were greater among older children. Incidence rate ratios comparing CMC and IC vs. no CMC/IC increased over time, indicating widening disparities.
conclusionsInvasive pneumococcal disease IRs among children with CMC/IC remain substantially higher than those without CMC/IC, and IRRs for children with risk conditions have increased over time. The risk-group disparities were more pronounced in older children. Better prevention strategies are needed to prevent IPD in children with risk conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.